
Home » FDA Approves Navidea’s Lymphoseek for Lymphatic Mapping in Solid Tumors
FDA Approves Navidea’s Lymphoseek for Lymphatic Mapping in Solid Tumors
The FDA has approved Navidea Biopharmaceuticals' supplemental new drug application for the expanded use of Lymphoseek injection for lymphatic mapping in solid tumors and adding Sentinel Lymph Node detection for breast cancer and melanoma to the approved indications.
Pharmaceutical Business Review
Upcoming Events
-
05Dec
-
07Dec
-
13Dec
-
14Apr